| SPECIAL REPORT—The top 20 pharma companies by 2022 revenue Goodbye, original COVID-19 vaccines: FDA updates shot guidance, pulls monovalent authorizations 2 embattled biotechs fight to survive as cash, options run dry Medtronic embarks on monthslong global layoffs, with total cuts unknown Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A Merck & Co. inks $11B Prometheus takeover, firing starting gun on race for blockbuster bowel market J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows AACR: Merck, Moderna show off therapeutic cancer vax data, with phase 3 launch before year-end New test detects Parkinson's biomarker before movement symptoms start FDA rejects Eli Lilly's ulcerative colitis prospect mirikizumab, citing manufacturing shortfalls Sanofi tops online global presence ranking for Big Pharmas, but new report exposes industry gaps at local level |
|
July 18-19, 2023 | Jersey City, NJ
Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $500 when you, Register Today!
|
|
| By Kevin Dunleavy 2022 was all about a return to normalcy from the COVID-19 pandemic. While a few companies continued to reap huge profits from COVID products, others benefited from a return to business as usual operations. It was a tough year for the global economy, but biopharma showed its resilience with all but a few recording revenue gains. |
|
|
|
By Zoey Becker The agency pulled its emergency use authorizations for the original COVID-19 vaccines and now says most people need only one dose of the updated shots. |
By Gabrielle Masson As difficult market conditions continue, two European-based biotechs are slashing costs and seeking ways to stay afloat as the end of the road nears. |
By Conor Hale With about 100,000 employees worldwide, the process of notifying people whether they still have a job could take months, the company said in a statement to Fierce Medtech. |
By Annalee Armstrong After circling around the crop of biotechs ripe for a takeover, Big Pharma companies have finally decided to strike. Merck & Co. made the first jab for Prometheus Biosciences on Sunday, then GSK struck Tuesday. |
By Nick Paul Taylor Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase bowel disease drug candidate. Months after midphase data sent Prometheus’ stock spiraling upward, Merck has agreed to a 75% premium over the biotech’s prior closing price to land a challenger to Roivant Sciences’ RVT-3101. |
By Angus Liu J&J and Legend's CAR-T therapy Carvykti slashed the risk of disease progression or death by a whopping 74% in multiple myeloma, according to a leaked abstract Fierce Pharma has obtained. The number exceeds analysts' expectations and puts Bristol Myers Squibb on notice. |
By Max Bayer Merck and Moderna are rapidly accelerating plans for a phase 3 trial of their cancer vaccine-Keytruda combo, hoping to launch a phase 3 trial before the end of the year. The companies found that the combination reduced the risk of recurrence or death in patients with melanoma by 44% compared to Keytruda alone. |
By Helen Floersh A nearly-decade-long study sponsored by actor Michael J. Fox's foundation has resulted in an assay that could pave the way for early intervention in Parkinson's disease—and maybe even new drugs that can prevent the disease. |
By Angus Liu Following the surprise FDA rejection of Alzheimer’s disease candidate donanemab in January, another Eli Lilly biologic drug has been met with an FDA cold shoulder. This time, manufacturing is to blame. |
By Ben Adams Sanofi is top of the pharma pile when it comes to online presence across the globe, but there is more work to be done when it comes to digital communications from the industry at a local level. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
Tuesday, April 25, 2023 | 11am ET / 8am PT How do drug developers move closer to collecting data that accounts for the full burden of disease and impact of a novel therapy? In this webinar, hear from industry innovators focused on ensuring that outcomes that have historically been considered hard-to-measure are no longer discounted due to difficulty of data capture. Register now.
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperAccelerated approval pathways create an additional layer of complexity in the chaotic oncology marketplace, leaving manufacturers of all sizes seeking a new commercialization model for launch success. Sponsored by: EVERSANA |
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
